Search Results

31 - 40 of 110 items :

  • "acute lymphoblastic leukaemia" x
Clear All
The prognostic value of mean platelet volume in cancer patients

the patients without VTE (median 7.2 fL, p = 0.034). Patients with baseline MPV 6.8 fL or below more often developed VTE compared to patients with higher MPV values (19% vs. 5.5%, p = 0.0244). Of the HL patients, in both the univariate and multivariate models, the patients with baseline low MPV levels had an above twofold increased risk of VTE development [ 29 ]. There are also reports about the prognostic role of platelet parameters in acute lymphoblastic leukemia (ALL) in pediatric patients [ 30 , 31 ]. ALL is the most common type of cancer

Open access
Methotrexate-Associated Biochemical Alterations in a Patient with Chronic Neurotoxicity

References Walker RW, Allen JC, Rosen G, Caparros B. Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol 1986; 4: 1845-50. García-Tena J, López-Andreu JA, Ferrís J, Menor F, Mulas F, Millet E, et al. Intrathecal chemotherapy-related myeloencephalopathy in a young child with acute lymphoblastic leukemia. Pediatr Hematol Oncol 1995; 12: 377-85. Oka M, Terae S, Kobayashi R, Sawamura Y, Kudoh K, Tha KK, et al. MRI in methotrexate

Open access
T-lymphoblastic leukemia/lymphoma in macedonian patients with Nijmegen breakage syndrome

the toes. He was admitted to the Hematology Department at the age of 9.5 with fever, disseminated lymphadenopaty, hepatosplenomegaly and leucocytosis of 27,000 × 10 9 /L. The evaluation of the peripheral blood smear showed the presence of 32.0% blast cells. The diagnosis of T-cell acute lymphoblastic leukemia (T-ALL) was established based on a standard immunohystological panel analysis. It was quite clear that the malignant disease in both children in this family was partly due to the clinical presentation of NBS. The patient was treated with the International

Open access
The influence of folate pathway polymorphisms on high-dose methotrexaterelated toxicity and survival in children with non-Hodgkin malignant lymphoma

. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol 2011; 67: 993-1006. 4. Erculj N, Kotnik BF, Debeljak M, Jazbec J, Dolzan V. Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia. Leuk Lymphoma 2012; 53: 1096-104. 5. Jazbec J, Kitanovski L, Aplenc R, Debeljak M, Dolzan V. No evidence of association of

Open access
In vitro drug sensitivity in canine lymphoma

References 1. Den Boer M.L., Harms D.O., Pieters R., Kazemier K.M., Gobel U., Körholz D., Graubner U., Haas R.J., Jorch N., Spaar H.J., Kaspers G.J., Kamps W.A., Van der Does-Van den Berg A., Van Wering E.R., Veerman A.J., Janka-Schaub G.E.: Patient stratification based on prednisolone-vincristineasparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003, 21, 262-3268. 2. Escherich G., Tröger A., Göbel U., Graubner U., Pekrun A., Jorch N., Kaspers G., Zimmermann M., zur Stadt U., Kazemier

Open access
Individualized Therapy: Role of Thiopurine S-Methyltransferase Protein and Genetic Variants

. Altered mercaptopurine metabolism, toxic effects and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphoblastic leukemia. J Pediatr 1991; 119: 985-9. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348: 529-37. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Gene 1980; 32: 651-62. Spyre-Vayron de la Moureyre C, Debuysere H, Fazio F, Sergent E

Open access
Decision Support Models and Software for the Differential Immunophenotype Diagnostics of Leukosis and Lymphomas/ Lēmumu pieņemšanas modeļi un programmnodrošinājums diferenciālajai imūnajai fenotipiskajai leikožu un limfomu diagnostikai/ Модели принятия решений и программное обеспечение для дифференциальной иммунофенотипической диагностики лейкозов и лимфом

. J. Karandikar and R. W. McKenna, “Characterization of Immunophenotypic Aberrancies in 200 Cases of B Acute Lymphoblastic Leukemia,” Am. J. Clin. Pathol., vol. 132(6), pp. 940-949, 2009. http://dx.doi.org/10.1309/AJCP8G5RMTWUEMUU [11] A. Hejlsberg, M. Torgersen, S. Wiltamuth, P. Golde, The C# Programming Language (Covering C# 4.0), 4th ed.. Microsoft Corporation, 2011, 815 p. [12] E. T. Ray. Learning XML, 2nd ed., O'Reilly Media, 2003, 418 p.

Open access
The Role of Supportive Therapy in Pediatric Malignancies

evidence based approach. New York, Springer, 2006,1363-1400. 4. Richard A. Larson, Richard K. Dodge, Charles A. Linker et al. A Randomized Controlled Trial of Filgrastim During Remission Induction and Consolidation Chemotherapy for Adults With Acute Lymphoblastic Leukemia: CALGB Study 9111. Blood Journal 1998;92(5):1556-1564 5. Anca Bacârea, Bogdana Dorcioman, Minodora Dobreanu et al. Tratamentul leucemiei acute mieloide – între beneficiu terapeutic si patologie iatrogenă – prezentare de caz. Revista Română de Medicină de Laborator Martie 2008

Open access
Chronic bullous disease of childhood – A case report / Hronična bulozna bolest Kod Dece – Prikaz Slučaja

;16(3):214-23. 10. Onodera H, Mihm MC Jr, Yoshida A, Akasaka T. Drug-induced linear IgA bullous dermatosis. J Dermatol 2005;32(9):759-64. 11. Ho JC, Ng PL, Tan SH, GiamYC. Childhood linear IgA bullous disease triggered by amoxicillin-clavulanic acid. Pediatr Dermatol 2007;24:40-4. 12. Polat M, Lenk N, Kürekçi E, Oztaş P, Artüz F, Alli N. Chronic bullous disease of childhood in a patient with acute lymphoblastic leukemia: possible induction by a drug. Am J Clin Dermatol 2007;8(6):389-91.

Open access
Original article. Efficacy of intravenous dexamethasone for the prevention of vomiting associated with intrathecal chemotherapy and ketamine sedation in children: a randomized, double-blinded, crossover, placebocontrolled trial

References 1. Onciu M. Acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009; 23:655-74. 2. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation N Engl J Med. 2009; 360:2730-41. 3. Holdsworth MT, Raisch DW, Winter SS, Chavez CM. Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron. Support Care Cancer. 1998; 6:132-8. 4. Langston

Open access